A Phase 2 interventional study of VX-561 and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 48 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-25.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 38th largest by enrollment, is one of 3 that started in 2019, is one of 17 in phase 2, and was the 62nd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 3 started in 2019.
This study's enrollment of 77 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 57th largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2019, is one of 21 in phase 2, and was the 84th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received IVA 150 milligrams (mg) orally every 12 hours (q12h) in the treatment period for 12 weeks.
Drug: IVA · Drug: Placebo
Participants received VX-561 25 mg orally daily (qd) in the treatment period for 12 weeks.
Drug: VX-561 · Drug: Placebo
Participants received VX-561 50 mg orally qd in the treatment period for 12 weeks.
Drug: VX-561 · Drug: Placebo
Participants received VX-561 150 mg orally qd in the treatment period for 12 weeks.
Drug: VX-561 · Drug: Placebo
Participants received VX-561 250 mg orally qd in the treatment period for 12 weeks.
Drug: VX-561 · Drug: Placebo
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline at Week 12
Absolute Change in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: From Baseline at Week 12
Observed Pre-Dose Concentration (Ctrough) of VX-561 and Its Metabolites (M1-VX-561 and M6-VX-561) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame: At Week 4
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to Week 16
| Milestone | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg |
|---|---|---|---|---|---|
| Started | 12 | 6 | 11 | 24 | 24 |
| Full analysis set | 11 | 6 | 11 | 23 | 24 |
| Completed | 11 | 4 | 11 | 22 | 24 |
| Not completed | 1 | 2 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Randomized, never dosed | 1 | 0 | 0 | 1 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Ivacaftor | VX-561: 150 mg | VX-561: 250 mg |
|---|---|---|---|
| Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | -0.8 (-6.2 to 4.7) | 3.1 (-0.8 to 7.0) | 2.7 (-1.0 to 6.5) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Ivacaftor | VX-561: 150 mg | VX-561: 250 mg |
|---|---|---|---|
| Absolute Change in Sweat Chloride (SwCl) | 0.9 (-9.5 to 11.3) | 3.3 (-4.6 to 11.2) | -6.5 (-14.1 to 1.2) |
| nanogram per milliliter (ng/mL) | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg |
|---|---|---|---|---|---|
| VX-561: Week 4 | — | 26.1 ± 24.7 | 123 ± 61.6 | 458 ± 273 | 1100 ± 856 |
| M1-VX-561: Week 4 | — | 18.1 ± 17.7 | 108 ± 58.6 | 378 ± 213 | 739 ± 407 |
| M6-VX-561: Week 4 | — | NA ± NA | 59.8 ± 34.0 | 211 ± 189 | 370 ± 233 |
| IVA: Week 4 | 952 ± 766 | — | — | — | — |
| M1-IVA: Week 4 | 1330 ± 774 | — | — | — | — |
| M6-IVA: Week 4 | 662 ± 398 | — | — | — | — |
| participants | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg |
|---|---|---|---|---|---|
| Participants with AEs | 8 | 4 | 8 | 21 | 23 |
| Participants with SAEs | 1 | 2 | 2 | 2 | 1 |
Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ivacaftor | 0/11 (0%) | 1/11 (9.1%) | 8/11 (72.7%) |
| VX-561: 25 mg | 0/6 (0%) | 2/6 (33.3%) | 4/6 (66.7%) |
| VX-561: 50 mg | 0/11 (0%) | 2/11 (18.2%) | 8/11 (72.7%) |
| VX-561: 150 mg | 0/23 (0%) | 2/23 (8.7%) | 17/23 (73.9%) |
| VX-561: 250 mg | 0/24 (0%) | 1/24 (4.2%) | 20/24 (83.3%) |
| Event | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg |
|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 1/11 | 1/6 | 2/11 | 2/23 | 1/24 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 0/11 | 1/6 | 0/11 | 0/23 | 0/24 |
| Forced expiratory volume decreasedInvestigations | 0/11 | 1/6 | 0/11 | 0/23 | 0/24 |
| Event | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg |
|---|---|---|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/11 | 2/6 | 0/11 | 2/23 | 0/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/11 | 1/6 | 1/11 | 6/23 | 1/24 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 2/11 | 0/6 | 2/11 | 2/23 | 4/24 |
| NasopharyngitisInfections and infestations | 2/11 | 0/6 | 0/11 | 0/23 | 3/24 |
| Aspartate aminotransferase increasedInvestigations | 0/11 | 1/6 | 2/11 | 1/23 | 1/24 |
| Blood creatine phosphokinase increasedInvestigations | 1/11 | 0/6 | 2/11 | 0/23 | 1/24 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/11 | 1/6 | 1/11 | 2/23 | 1/24 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/11 | 0/6 | 0/11 | 4/23 | 0/24 |
| Respiration abnormalRespiratory, thoracic and mediastinal disorders | 2/11 | 0/6 | 1/11 | 4/23 | 0/24 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 0/11 | 0/6 | 1/11 | 4/23 | 3/24 |
| Age, Continuous(years) | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 33.3 ± 11.7 | 33.0 ± 10.6 | 27.8 ± 9.0 | 32.5 ± 8.5 | 37.4 ± 11.4 | 33.5 ± 10.4 |
| Sex: Female, Male(Participants) | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 2 | 3 | 8 | 9 | 26 |
| Male | 7 | 4 | 8 | 15 | 15 | 49 |
| Ethnicity (NIH/OMB)(Participants) | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 | 0 | 2 |
| Not Hispanic or Latino | 11 | 6 | 10 | 22 | 24 | 73 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 10 | 6 | 11 | 23 | 24 | 74 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(percentage points) | Ivacaftor | VX-561: 25 mg | VX-561: 50 mg | VX-561: 150 mg | VX-561: 250 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 74.0 ± 21.2 | 63.6 ± 22.4 | 66.8 ± 17.4 | 72.6 ± 17.3 | 73.9 ± 17.0 | 71.6 ± 18.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Apr 2019 to primary completion in Aug 2020, 16 months.
Results were first posted in Jan 2022, 1 year 5 months after primary completion. A results delay was requested in Aug 2021.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 16 months is close to that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →